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Background/aim: Hypoxic-ischemic encephalopathy (HIE) is a condition that may cause multiple organ dysfunction and has a high
rate of mortality and morbidity. Therapeutic hypothermia is the only proven treatment that decreases the sequel and mortality rate of
neonates that are born after 36 weeks of pregnancy and have moderate-severe HIE.
Material and method: Our study was a single-center, retrospective study that includes newborns (gestational age ≥ 36 weeks) who
underwent therapeutic hypothermia due to hypoxic-ischemic encephalopathy between 2010 and 2020. We evaluated 125 patients who
were diagnosed with moderate to severe HIE and received therapeutic hypothermia. Demographic and clinical data were obtained from
electronic medical records and patient files. The patients were separated into two groups as exitus group (n = 39) and discharged group
(n = 86). We aimed to evaluate factors affecting mortality.
Results: We determined that the median resuscitation times were longer in the delivery room [retrospectively, 10th minutes (0–30) vs. 1
min (0–20), p < 0.05], the tenth min APGAR scores were lower [respectively, 4 (0–7) vs. 6 (3–10), p < 0.05], and the median pH value in
the first blood gas taken was lower [respectively, 6.87 (6.4–7.14) vs. 6.90 (6.58–7.12), p < 0.05] in the exitus group. We also determined
that multiple organ dysfunction is seen more often in the exitus group.
Conclusion: This study demonstrated that the depth of acidosis in the blood gas, multiple organ dysfunction, and the existence of earlyonset seizures are the signs of poor prognosis. Therefore, physicians need to be aware of such prognostic factors to follow these patients
more closely in terms of possible complications and to inform their parents.
Keywords: Hypoxic ischemic encephalopathy, neonatal encephalopathy, perinatal asphyxia, therapeutic hypothermia

1. Introduction
Hypoxic-ischemic encephalopathy (HIE) is an acute and
possibly progressive condition that emerges as a result of
intrapartum or postpartum hypoxia and ischemia. Due
to insufficient gas exchange across the placenta in the
intrauterine period or insufficient pulmonary ventilation in
the postnatal period, oxygen and carbon dioxide exchange is
disrupted and the patients develop hypoxemia, hypercarbia,
and acidosis [1,2]. The incidence rate of HIE is 2–9 per
thousand live births [3]. According to the 2008 data of the
Turkish Neonatology Association, the rate of HIE in Turkey
is 0.26% [4]. HIE is still a significant cause of mortality in
neonates. In survivors, it may leave significant neurologic
sequels such as vision and/or hearing loss, epilepsy, mental
retardation, and cerebral palsy [1,5]. To reduce to mortality
and sequel rates of neonates that are experienced HIE,
neuroprotective treatments should be started as soon as

possible. Nowadays, therapeutic hypothermia is the most
trustworthy and strong option which effectiveness-proven
in reducing mortality and morbidity among neuroprotective
treatments [6]. A meta-analysis of 11 randomized controlled
trials published in 2013 found that hypothermia treatment
reduced death and neurodevelopmental impairment in
1505 infants with HIE [7].
In this study, we aimed to evaluate the factors related
to mortality of moderate-severe HIE patients who were
applied therapeutic hypothermia in our neonate intensive
care unit within 11 years.
2. Material and method
2.1.Patient selection
This study had ethical approval from Faculty of Medicine
of İnönü University, Malatya, Turkey, and was designed as
a single-center, retrospective cohort study.
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The neonates who were diagnosed with moderatesevere HIE, hospitalized in our intensive care unit, and
received therapeutic hypothermia treatment between the
dates of January 2010 and December 2020 were included in
our study. Electronic medical records and patient files were
reviewed retrospectively. Data taken from the patients’ folder
retrospectively were as follows: demographic information
(birth weight, sex, age of pregnancy, delivery method and
place, maternal age), laboratory examinations (blood gas,
kidney and liver function tests, complete blood count, and
the electrolyte levels), seizure history, need for intubation,
amplitude-integrated
electroencephalogram
(aEEG)
monitoring and cranial ultrasonography findings. Patients
were separated into two groups as exitus and discharged
ones. To determine the factors affecting mortality, a series
of analyses were carried out between the groups.
2.2. Management and protocol of therapeutic
hypothermia
In our unit, the Tecotherm Neo device (Inspiration
Healthcare, UK) is used to induce therapeutic hypothermia.
During the treatment, patients are being monitored. The
core temperature of the patients is monitored with a rectal
temperature probe and stabilized between 33.5 ℃–34.5 ℃
for the entire 72 h. Vital findings and rectal temperature
values of the patients are hourly recorded. Urine output,
blood gas, and kidney-liver function tests of the patients
are closely followed. Blood tests are taken within the first
24 h and repeated later when necessary.
Hypothermia treatment indications in our unit are
as follows [4, 8, 9]: 1) The neonates who are in the first
postnatal 6 h and age of pregnancy is ≥ 36 weeks; 2) Cord
or blood gas which is taken in the first hour of after birth:
pH value < 7.00 or base excess (BE) < –16 mmol/L; 3) 10th
min APGAR score < 5 or continued resuscitation need;
4) Moderate-severe HIE diagnosis in clinical evaluation
according to Sarnat and Sarnat staging; 5) The existence of
moderate-to-severe trace irregularity on aEEG if used; 6)
Accompanied by low APGAR or encephalopathy findings
in patients with pH value < 7.00–7.15 and BE –10–(–16).
2.3. Statistical analysis
SPSS for Windows version 21.0 packaged software was
used for statistical analysis. Shapiro Wilk test was used
in the eligibility check of continuous variables to normal
distribution. Independent student t-test was used in the
normally distributed variables’ 2 independent groups
comparison. Mann Whitney U test was used in the
nonnormally distributed variables’ 2 independent groups
comparison. While normal continuous data were stated
as average ± standard deviation; nonnormal continuous
data were stated as median (minimum-maximum). Chisquared and Fischer exact analysis were used in the test
of correlation among categorical variables. P < 0.05 was
accepted as significant statistically.

3. Results
Between our study’s dates, 14,459 patients were
hospitalized in our neonate intensive care unit. One
hundred and twenty-five patients who were diagnosed
with moderate-severe HIE and underwent hypothermia
treatment during the period were included in the study.
One hundred and eighteen of the patients were referred
from other centers and only 7 (5.6%) patients were babies
born in our hospital. During the follow-up, 68.8% (n =
86) of the patients were discharged from the hospital, and
31.2% (n = 39) of them died. Demographic characteristics
(birth weight, sex, maternal age, gestational week, and
delivery method) of both groups were statistically similar.
When the exitus group was compared with the discharged
group; we determined that the neonates who died had
longer median resuscitation times in the delivery room
[respectively, 10 (0–30) vs. 1 (0–20), p < 0.05], and lower
10th-min median APGAR scores [respectively, 4 (0–7) vs.
6 (3–10), p < 0.05] (Table 1). The distribution of asphyxia
etiology of both groups was statistically similar (Table 2).
According to the laboratory results; exitus group versus
discharged group; the median PH value [respectively, 6.87
(6.4–7.14) vs. 6.90 (6.58–7.12), p < 0.05], mean HCO3
value (respectively, 8.23 ± 2.67 vs. 10.33 ± 2.48, p < 0.05)
and mean BE value [respectively, –22.39 ± (–4.42) vs.
–19.46 ± (–3.95), p < 0.05] were lower than discharged
group. Also, kidney (blood urea nitrogen and creatinine)
and liver (aspartate aminotransferase [AST] and alanine
aminotransferase [ALT]) function tests and values of
potassium and phosphorus in the exitus group were higher.
Levels of platelet and calcium were lower than discharged
group (p < 0.05) (Table 3).
In the clinical observation of the exitus group,
pulmonary hypertension progression and needs for
peritoneal dialysis, surfactant, inotrope, and intubation
were more frequent (p < 0.05). We determined that the
frequency of seizure, abnormal aEEG, abnormal cranial
ultrasonography findings were higher in the exitus group.
We also determined that the first seizure time was earlier
in the exitus group (p < 0.05) (Table 4).
We examined our patients in 2 groups as moderate and
severe HIE. The mortality rate was statistically higher in
the severe group (respectively, 86.1% vs. 9%, p < 0.001). In
addition, liver and kidney dysfunction was more common
in the group with severe HIE. Also, low pH and BE in the
first blood gas were statistically significant in the severe
group. The number of patients who had seizures was also
higher in the severe HIE group (Table 5).
4. Discussion
Even though hypothermia is the only efficient proven
treatment, HIE is still one of the significant causes of
neonatal mortality. Because it may result in serious sequels
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Table 1. Demographic characteristics and first evaluation of the patients who were exitus and discharged groups.
All patients
(n = 125)

Discharged groups
(n = 86)

Exitus groups
(n = 39)

p-value†

Birth weight g*

3175.0 ± 619.6

3194.6 ± 491.8

3131.7 ± 580.6

0.533

Gestational weeks week*

38.68 ± 1.89

38.66 ± 2

38.72 ± 1.5

0.881

Gender (female) n (%)

53 (42.4)

33 (38.3)

20 (51.2)

0.247

Mode of delivery (Caesarean) n (%)

58 (46.4)

39 (45.3)

19 (48.7)

0.876

Maternal age years*

29.38 ± 6.8

28.7 ± 6.7

30.87 ± 6.9

0.102

Referred from other centers n (%)

118 (94.4)

84 (97.67)

34 (87.17)

0.03

Passive cooling n (%)

76 (60.8)

48 (55.8)

28 (71.7)

0.134

Active cooling starting time hours*

2.40 ± 1.8

2.48 ± 1.9

0.72 ± 0.4

0.570

First rectal temperature °C**

35 (29–37)

35 (32–37.3)

34.5 (29–36.2)

0.005

10th min APGAR score**

5 (0–10)

6 (3–10)

4 (0–7)

<0.05

Resuscitation time minutes**

2 (0–30)

1 (0–20)

10 (0–30)

<0.05

*Values are given as mean ± standard deviation. ** Values are given as median (min-max). †Results of statistical comparisons between
discharged and exitus groups.
Table 2. Etiology distribution patients of hypoxic-ischemic encephalopathy.
All patients
(n = 125)

Discharged groups Exitus groups
(n = 86)
(n = 39)

Meconium aspiration syndrome n (%)

38 (30.4)

27 (31.4)

11 (28.2)

Difficult delivery/Prolonged labor n (%)

42 (33.6)

30 (34.9)

12 (30.8)

Cord entanglement n (%)

9 (7.2)

7 (8.1)

2 (5.1)

Cord prolapse n (%)

4 (3.2)

4 (4.6)

0

Placental abruption n (%)

20 (16)

7 (8.1)

2 (5.1)

Fetal distress n (%)

9 (7.2)

9 (10.5)

11 (28.2)

Chorioamnionitis n (%)

2 (1.6)

1 (1.2)

1 (2.5)

Anemia n (%)

1 (0.8)

1 (1.2)

0

p-value†

0.269

†Results of statistical comparisons between discharged and exitus groups.

for survivors, a better knowledge of prognostic factors about
HIE is important for physicians who are treating patients. It
would also allow physicians to inform patient relatives better
about the neonate’s prognosis. The mortality rate is reported
between 10%–60%, and approximately 24% of patients in
neonatal intensive care units died before discharge. In
survivors, motor and behavioral problems are seen as
well as cerebral palsy and audio-visual problems [10–12].
According to the Turkish Neonatology Association 2008
data, the mortality rate of HIE-diagnosed patients is 22.6%
[4]. Since our neonatal intensive care unit is the reference
center in the region, 118 of the patients were referred from
other centers and only 7 (5.6%) patients were babies born
in our hospital. Passive cooling had been started in 76 of
the patients that came to our unit from other centers. In
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our study group, we found the mortality rate of moderatesevere HIE diagnosed patients who underwent hypothermia
treatment as 31.2% which is similar to literature data.
The neuroprotective efficiency of hypothermia
treatment depends on the stage of HIE and the starting
time of treatment. It is known that the mortality rate of
Sarnat stage 3 HIE-diagnosed neonates is higher [13]. In
our study group, the mortality rate of severe HIE patients
was significantly higher than the moderate HIE group.
The most effective period for hypothermia treatment is
the period before the development of secondary energy
deficiency [13]. Therefore, hypothermia should start in the
postnatal first 6 hours. We started hypothermia treatment
in postnatal first 6 h of all patients and the starting times of
the two groups were statistically similar.
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Table 3. Blood gas values taken in the first hour and biochemical and complete blood count parameters taken in the 24th h of patients.
All patients
(n = 125)

Discharged groups Exitus groups
(n = 86)
(n = 39)

p-value†

PH**

6.89 (6.4–7.14)

6.90 (6.58–7.12)

6.87 (6.4–7.14)

<0.05

Base excess* mmol/L

–20.37 ± 4.30

–19.46 ± 3.95

–22.39 ± 4.42

<0.05

Bicarbonate* mmol/L

9.68 ± 2.72

10.33 ± 2.49

8.23 ± 2.67

<0.05

The partial pressure of carbon dioxide* mmHg

49.73 ± 24.93

47.67 ± 21.60

54.28 ± 30.90

0.176

White blood cell* 10^3/uL

24.60 ± 9.94

23.48 ± 9.92

27.08 ± 9.65

0.06

Hemoglobin* g/dL

17.20 ± 5.85

17.27 ± 2.89

15.95 ± 3.64

0.109

Platelet* 10^3/uL

209.90 ± 83.40

227.36 ± 78.88

171.41 ± 81.05

<0.05

Potassium* mmol/L

5.23 ± 1.19

5.07 ± 0.908

5.64 ±1.64

0.016

Calcium* mg/dL

8.02 ± 1.21

8.25 ± 0.84

7.67 ± 1.18

0.003

Phosphorus* mg/dL

6.17 ± 2.41

5.38 ± 1.33

8.11 ± 3.27

<0.05

Uric acid* mg/dL

9.36 ± 3.64

8.25 ± 2.72

12.17 ± 4.19

<0.05

Lactate dehydrogenase** U/L

1855 (611–11147)

1684 (611–11147)

3320 (706–6650)

0.016

Blood Urea Nitrogen* mg/dL

14.67 ± 6.37

13.48 ± 4.73

16.87 ± 8.88

0.008

Creatinine** mg/dL

0,97 (0.3–2.8)

0.80 (0.3–2)

1.07 (0.7–2.8)

<0.05

Aspartate aminotransferase** U/L

173 (31–4500)

135 (31–3607)

549 (45–4500)

<0.05

Alanine aminotransferase** U/L

55 (9–4200)

39 (9–1432)

267 (16–4200)

<0.05

*Values are given as mean ± standard deviation. ** Values are given as median (min-max). †Results of statistical comparisons between
discharged and exitus groups.
Table 4. The clinical follow-up information of patients
All patients
(n = 125)

Discharged groups
(n =86)

Exitus groups
(n = 39)

p-value†

Seizures in the first 72 h n (%)

69 (55.2)

37 (43)

32 (82.1)

<0.05

First seizures time hour*

4 (1–60)

6 (1–60)

2 (1–48)

<0.05

Abnormal aEEG trace n (%)

37 (29.6)

21 (24.4)

16 (41)

0.001

Abnormal cranial USG n (%)

65 (52)

30 (34.8)

35 (89.7)

<0.05

Peritoneal dialysis n (%)

15 (12)

2 (2.32)

13 (33.33)

<0.05

Inotropic support n (%)

68 (54.4)

32 (37.20)

36 (92.30)

<0.05

Surfactant treatment n (%)

25 (20)

10 (11.62)

15 (38.46)

0.001

Pulmonary hypertension n (%)

27 (21.6)

8 (9.30)

19 (48.71)

<0.05

Intubation rate n (%)

74 (59.2)

31 (36)

37 (94.8)

<0.001

*Values are given as median (min-max). †Results of statistical comparisons between discharged and exitus groups.

In neonates who are exposed to asphyxia, to protect
the vital organs such as the heart and brain from hypoxia,
blood flow reorganizes (diving reflex). This situation
increases the damage rate of the organs which are directly
affected by hypoxia such as the liver, kidney, and bowel.
In their study, Havkins et al. [14] found that 80% liver
damage, 72% kidney damage, 72% cardiac damage, and
54% hematological damage were accompanied by central

nervous system damage to all patients who were exposed
to asphyxia. They predict that low APGAR, low pH, and
low BE in patients have the same predictive value as
evidence of organ dysfunction. According to the study
performed on 144 asphyxia neonates by Şah et al. [15],
it was determined that at least one organ dysfunction
appears except the nervous system. Alsina et al. [16] had
evaluated 79 HIE patients in terms of renal, cardiovascular,
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Table 5. Evaluation of patients according to the grade of HIE.
All patients
(n = 125)

Moderate HIE
(n = 89)

Severe HIE
(n = 36)

p-value†

Mortality rate n (%)

39 (31.2)

8 (9)

31 (86.1)

<0.001

PH**

6.89 (6.4–7.14)

6.94 (6.6–7.12)

6.80 (6.4–7.14)

<0.001

Base excess* mmol/L

–20.37 ± 4.30

–19.23 ± 3.35

–23.23 ± 5.08

<0.001

Blood urea nitrogen* mg/dL

14.67 ± 6.37

13.65 ± 4.89

16.64 ± 8.96

0.077

Creatinine** mg/dL

0.97 (0.3–2.8)

0.8 (0.3–2.0)

1.07 (0.6–2.8)

0.001

Aspartate aminotransferase** U/L

173 (31-4500)

136.5 (31–3607)

549 (32–4500)

<0.001

Alanine aminotransferase** U/L

55 (9-4200)

40 (9–1432)

267 (23–4200)

<0.001

Platelet* 10^3/uL

209.90 ± 83.40

220.34 ± 82.86

184.08 ± 80.11

0.027

Seizures in the first 72 h n (%)

69 (55.2)

37 (41.57)

32 (88.8)

<0.001

*Values are given as mean ± standard deviation. ** Values are given as median (min-max). †Results of statistical comparisons
between moderate and severe HIE groups.

respiratory, hepatic, hematological systems, and pH and
electrolyte imbalance in their study. They found that pH
and electrolyte imbalance and hepatic damage were most
frequently seen. In their study, they determined that
the severity of multi-organ dysfunction and the degree
of hypoxia shows a positive correlation. In our study
population, the rate of multi-organ dysfunction was higher
in patients with severe HIE, following the literature.
HIE is the most important reason for neonatal
convulsions and progress to convulsion is observed in the
first 24 h in 50%–70% of neonates with HIE [17]. While
convulsions are seen in the first hours for most of the
cases, convulsions start right after the birth when it comes
to severe HIE cases [18]. In addition to the frequency of
seizures in the exitus group, we also determined that in our
study the time of first seizures was earlier.
Liver damage mostly stems from hypoperfusion
rather than hypoxia. According to the studies performed
by Muniraman et al. [19], it was determined that
transaminase levels (AST and ALT) increase in correlation
with HIE grade. In their study, Sharma et al. [20] found
that the severity of hepatic dysfunction correlates well with
the increasing severity of asphyxia. Acute kidney damage
is also one of the complications related to mortality and is
most frequent among asphyxiating neonates. In their study
Grossman et al. [21] found that, acute kidney damage
incidence is 45% and is also related to neonatal mortality.
In an 8-year retrospective study by Michnlewicz et al.
[22], they found that AST, ALT, and creatinine levels were
significantly higher and platelet levels were lower in the
group with severe HIE. In their prospective cohort study
with 150 infants with HIE, Acharya et al. [23] found that
hypocalcemia, hyperkalemia, and high urea-creatinine
levels were correlated with HIE grade. A higher incidence
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of multi-organ dysfunction was also observed in the exitus
group and the severe HIE group in our study; similar to the
literature. Elevation in transaminases and kidney function
disruption rate was significantly higher in the exitus group
and it was correlated with HIE grade. A study has shown
that neonates with HIE who had thrombocytopenia had
higher mortality [24]. Platelet values were statistically
lower in the exitus group of our study. In a meta-analysis
by Lakshminrusimha et al. [25], they found the pulmonary
hypertension rate to be 22% in 303 infants with HIE and
found that it was associated with mortality, a higher need
for dialysis, surfactant and inotropic support, and a higher
intubation rate. The rate of pulmonary hypertension in our
patients was 21.6% and it was significantly higher in the
exitus group.
In this study which we present our experience of 11
years, a deep acidosis in the first blood gas, abnormalities
in laboratory values (electrolyte abnormality, liver, and
kidney dysfunction) measured at 24th h, early-onset
seizures, and higher intubation rates were associated with
a high risk of mortality. HIE is the 3rd most common reason
for death in the neonatal period. The risk of multi-organ
failure development and sequel rate for the survivors is
high in these patients. It is important to know and specify
the poor prognostic factors early in this group that have
high rates of mortality and forensic cases. This will help
both to be prepared for the complications that may be
encountered in the follow-up stage and intervene at early
stages, and inform the parents in advance about the serious
problems that may be encountered in the future.
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